LeonaBio (LONA) director receives 28,000 stock options at $8.35 exercise price

Rhea-AI Filing Summary

LeonaBio, Inc. director Michael A. Panzara received a grant of stock options covering 28,000 shares of common stock. The options have an exercise price of $8.35 per share and expire on June 22, 2036.

The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting that occurs after June 22, 2026. This is a compensation-related award rather than an open-market transaction.

Insider Trade Summary

1 transaction reported

Mixed 1 txn

Insider Panzara Michael A.

Role null

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (Right to Buy)	28,000	$0.00	--

Holdings After Transaction: Stock Option (Right to Buy) — 28,000 shares (Direct, null)

Footnotes (1)

1. [object Object]

Key Figures

Options granted: 28,000 options Exercise price: $8.35 per share Expiration date: June 22, 2036 +2 more

5 metrics

Options granted 28,000 options Stock Option (Right to Buy) grant to director

Exercise price $8.35 per share Conversion or exercise price of options

Expiration date June 22, 2036 Option term end date

Shares underlying options 28,000 shares Underlying LeonaBio common stock

Shares held after transaction 28,000 derivative securities Total options directly owned following grant

Key Terms

Stock Option (Right to Buy), Outside Director Compensation Policy, vest

3 terms

Stock Option (Right to Buy) financial

"security_title: Stock Option (Right to Buy)"

Outside Director Compensation Policy financial

"The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy."

vest financial

"The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 06/24/2026 - 06:33 PM Accepted by SEC EDGAR 06/24/2026 - 06:33 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Panzara Michael A.

(Last) (First) (Middle)

C/O LEONABIO, INC.

18706 NORTH CREEK PARKWAY, SUITE 104

(Street)

BOTHELL WASHINGTON 98011

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
LeonaBio, Inc. [ LONA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/23/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (Right to Buy)	$8.35	06/23/2026		A		28,000		(1)	06/22/2036	Common Stock	28,000	$0	28,000	D

Explanation of Responses:

1. The shares subject to the option will vest on the earlier of (i) June 23, 2027, or (ii) the day immediately before the date of the next annual meeting of the Issuer's stockholders that occurs after June 22, 2026. The option reported was granted pursuant to the terms of the Issuer's Outside Director Compensation Policy.

	/s/ Mark Worthington, Attorney in fact for Michael A. Panzara	06/24/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

FAQ

What did LeonaBio (LONA) director Michael Panzara report on this Form 4?

Michael Panzara reported receiving a grant of stock options for 28,000 shares of LeonaBio common stock. These options are a compensation-related award, not an open-market trade, and provide the right to buy shares at a fixed exercise price.

How many LeonaBio (LONA) stock options were granted to Michael Panzara?

The filing shows a grant of stock options covering 28,000 shares of LeonaBio common stock. This entire amount is held directly after the transaction, indicating a new award rather than a sale or exercise of previously held options.

What is the exercise price and expiration date of Michael Panzara’s LeonaBio options?

The options have an exercise price of $8.35 per share and expire on June 22, 2036. This means Panzara can choose to buy shares at $8.35 any time before that expiration if vesting conditions are met.

When do Michael Panzara’s LeonaBio (LONA) stock options vest?

The options will vest on the earlier of June 23, 2027, or the day immediately before the next annual stockholder meeting occurring after June 22, 2026. Vesting determines when the options become exercisable for common shares.

Is Michael Panzara’s Form 4 for LeonaBio a stock purchase or a compensation grant?

The Form 4 reflects a compensation grant, not an open-market stock purchase. It records an award of stock options at no cost per option, giving Panzara the right to buy 28,000 shares at an $8.35 exercise price if vesting conditions are satisfied.

Were these LeonaBio (LONA) options granted under a specific company policy?

Yes. The footnote explains that the option grant was made under LeonaBio’s Outside Director Compensation Policy. This indicates the award is part of the standard compensation structure for non-employee directors rather than a discretionary market transaction.